Testing two medications together for rare cancers with a specific genetic mutation

This trial is testing dabrafenib plus trametinib — two medications used together — in patients with rare, advanced cancers that have a specific genetic change called BRAF V600E. The study includes children (age 1 and older) and adults whose doctors have already decided to start this treatment. Researchers want to learn more about how well this medication combination works for these uncommon cancer types.

Most information about this medication comes from studies in melanoma and lung cancer, but many other rare cancers also have this same genetic mutation. This trial exists to gather real-world evidence about whether the treatment is effective for these less common tumor types.